Prognostic Indices in Transitional Cell Carcinoma of the Bladder

British Journal of Urology

Volumn 62, Issue 2, 1988, Pages 103-109

  ABEL, P D ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER CANCER; CANCER STAGING; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BLADDER NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; HUMAN; NEOPLASM INVASIVENESS; PROGNOSIS;

EID: 0023711787     PISSN: 00071331     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.1988.tb04286.x     Document Type: Article

References (69)

1. Assessment of serum CA 19.9 as a tumour marker in patients with carcinoma of the bladder and prostate.
2. Should pTl transitional cell cancers of the bladder still be classified as superficial
3. Differing interpretations of the pT category and grade of transitional cell cancer of the bladder by pathologists
4. Immunological aspects of bladder cancer.
5. Noninvasive papillary carcinoma of the bladder associated with carcinoma‐in‐situ.
6. The accuracy of clinical vs surgical staging.
7. Changes in grade and stage of recurrent bladder tumors.
8. Loss of basement membrane components by invasive tumours but not by their benign counterparts.
9. Blood vessel invasion in human bladder cancer.
10. Treatment of T3 bladder cancer: controlled trial of preoperative radiotherapy and radical cystectomy versus radical radiotherapy.
11. Epithelioma of the genito‐urinary organs.
12. TMN (1978) in bladder cancer: use and abuse.
13. Survival rates of patients with bladder tumours. An experience of 1744 cases.
14. Blood‐group precursor T‐antigen expression in human bladder carcinoma.
15. Longitudinal study of patients with bladder cancer: factors associated with disease recurrence and progression.
16. Collagen IV staining pattern in bladder carcinoma: relationship to prognosis.
17. Prognostic factors in superficial bladder tumors.
18. Transitional cell cancer: upper tracts and bladder.
19. Bladder tumors and associated proliferative mucosal lesions.
20. The correlation of T1 bladder tumour histology with prognosis and follow‐up requirements.
21. Cytogenic analysis: a potential index for recurrence of early carcinoma of the bladder.
22. Prognosis in early carcinoma of the bladder based on chromosmal analysis.
23. Histopathology and classification of urinary bladder carcinoma
24. Pathology of human bladder cancer and related lesions.
25. Identification of vessels by lectin‐immunoperoxidase staining of endothelium: possible applications in urogenital malignancies.
26. The Copenhagen bladder cancer project.
27. Treatment of malignant disease of the prostate and bladder.
28. The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histological grading
29. Superficial bladder cancer: progression and recurrence.
30. Ta and T1 bladder cancer: location, recurrence and progression.
31. Invasive bladder cancer: tumor configuration, lymphatic invasion and survival.
32. Classification of bladder tumours.
33. Carcinoma of the bladder: characteristic modes of local invasion.
34. Infiltrating carcinoma of the bladder: relation of depth of penetration of the bladder wall to incidence of local extension and metastasis.
35. Mode of presentation of bladder cancer: reassessment of the problem.
36. The grade and pathologic stage of bladder cancer.
37. Tissue polypeptide antigen as a predictor for genitourinary cancers and their metastases.
38. Prostate cancer consensus hampered by lack of data.
39. Altered reactivity for ABH antigens in transitional cell carcinomas of the urinary bladder—a study of the mechanisms involved.
40. ABH antigen detectability in normal and neoplastic urothelium. Influence of methodologic factors.
41. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.
42. Carcinoma of the urinary bladder: a pathologic study with special reference to invasiveness and vascular invasion.
43. Current clinical problems regarding bladder tumors.
44. Histological study of vesical urothelium intervening between gross neoplasms in total cystectomy.
45. Intraurothelial cancer: carcinoma‐in‐situ, Bowen's disease of the urinary system: discussion of thirty cases.
46. Bladder cancer: factors affecting survival.
47. A DNA cytophotometric study of neoplastic field change in the human urinary bladder (abstract).
48. Analysis of the performance of pathologists in the grading of bladder tumors.
49. Morphometric grading of bladder tumors in comparison with histologic grading by pathologists.
50. The ultrastructure and pathobiology of urinary bladder cancer.
51. Grading in superficial bladder cancer. (1) Morphological criteria.
52. Prognostic factors in non‐infiltrating carcinoma of the bladder: a preliminary report.
53. Bladder carcinoma as a systemic disease.
54. Chromosome markers and progression in bladder cancer.
55. Pre‐cancerous changes in bladder epithelium.
56. The association of urothelial atypism with neoplasia: its importance in treatment and prognosis.
57. The association of urothelial abnormalities with neoplasia: a 10 year follow‐up.
58. Current perspectives in the management of high grade invasive bladder cancer.
59. The heterogeneity of invasive bladder carcinoma and different responses to treatment.
60. Prognostic significance of biopsy results of normal looking mucosa in cases of superficial bladder cancer.
61. Precursors of the blood‐group MN antigens as human carcinoma associated antigens.
62. Prognosis in carcinoma of the urinary bladder based upon tissue blood‐group ABH and Thomsen‐Friedenreich antigen status and karyotype of the initial tumour.
63. A 10 year analysis of chromosomes in non‐invasive papillary carcinoma of the bladder.
64. Blood group antigens in the normal and neoplastic bladder epithelium.
65. Biochemistry and genetics of the ABO, Lewis and P blood‐group systems.
66. The prevalence and significance of Brunn's nests, cystitis cystica and squamous metaplasia in normal bladders.
67. Urothelial dysplasia concomitant with bladder tumours: a determinant for future new occurrences in patients treated by full course radiotherapy.